Street Calls of the Week
Investing.com - TD Cowen has reiterated its Buy rating on UCB SA (BR:UCB) (OTC:UCBJY) with a price target of EUR255.00, highlighting the strong market potential of the company’s Bimzelx treatment. The company’s financial health score on InvestingPro is rated as "GREAT," with an impressive 73.38% gross profit margin and 25.56% revenue growth in the last twelve months.
The firm expressed "high conviction" in Bimzelx’s long-term potential, which it says has been reinforced by MLTX’s sonelokimab hidradenitis suppurativa (HS) results.
TD Cowen noted that Bimzelx has demonstrated "impressive real-world efficacy" that has "exceeded all expectations," positioning UCB as the incumbent in what it describes as a "large and growing HS market."
The research firm maintains its peak sales estimate for Bimzelx at over EUR6 billion, with more than EUR3 billion of that coming from the HS indication alone.
TD Cowen concluded that UCB remains a "clear Buy for the durable earnings growth" it offers investors.
In other recent news, Goldman Sachs has initiated coverage on UCB SA with a Buy rating. The investment bank set a price target of EUR250.00 for the company. This decision is based on the potential of UCB’s Bimzelx drug, which Goldman Sachs considers to have blockbuster potential. The bank forecasts peak sales of €7 billion for Bimzelx across various indications. These developments position UCB as a noteworthy opportunity within the European Biopharma sector. Investors may find this information relevant as it highlights the transformative impact Bimzelx could have on UCB’s future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.